Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

benzinga.com/markets/biotech/25/06/45797348/early-wins-regenxbios-gene-therapy-helps-duchenne-patients-walk-stronger-longer

RegenXBio Inc. (NASDAQ:RGNX) revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.
Updates include positive functional, safety, and biomarker data for RGX-202, REGENXBIO’s investigational gene therapy for Duchenne muscular dystrophy.
The data update looked at…

This story appeared on benzinga.com, 2025-06-05 15:43:44.
The Entire Business World on a Single Page. Free to Use →